Has Lucia Alvarez, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,886 in general payments to Lucia Alvarez, MD across 31 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Lucia Alvarez, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Lucia Alvarez, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Lucia Alvarez, MD

Cardiovascular Disease · Atlanta, GANPI 1477815207

Payments from drug & device makers

$1,886in general payments, 2019–2025

Across 31 payments — averaging $60.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Abbott$1K
Boston Scientific$443
Edwards Lifesciences$251
Heartflow, Inc.$103
Lantheus Medical Imaging, Inc.$22

What the payments were for

Travel & lodging$99753%
Food & beverage$88947%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Abbott	8	$1,067
Boston Scientific	19	$443
Edwards Lifesciences	2	$251
Heartflow, Inc.	1	$103
Lantheus Medical Imaging, Inc.	1	$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

WATCHMAN Access System$149
FFRct$103

How this compares

$1,886 in reported general payments places this provider in the 45th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia →

Medicare billing

Part B allowed, 2024

$149,308

Medicare patients

1,244

Services billed

2,499

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	124	$142,411
XareltoRivaroxaban	19	$29,548
Metoprolol Succinate	128	$1,498
Ezetimibe	67	$1,433
Atorvastatin Calcium	126	$863
Rosuvastatin Calcium	86	$824
Losartan Potassium	100	$753
Flecainide Acetate	21	$663
Lisinopril	48	$519
Midodrine Hcl	14	$478
Amlodipine Besylate	94	$422
Potassium Chloride	26	$407
Torsemide	20	$311
Hydralazine Hcl	25	$270
Spironolactone	13	$249

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Atlanta

Elizabeth OfiliAtlanta$4.5M
Sanjay YadavAtlanta$3.7M
Arshed QuyyumiAtlanta$3.4M
Bobby KhanAtlanta$1.7M
Michael MorrisAtlanta$1.1M
Modele OgunniyiAtlanta$1M
Joseph MillerAtlanta$771K
Mani VannanAtlanta$716K
Gautam KumarAtlanta$639K
Melvin EcholsAtlanta$461K

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →